A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Status:
RECRUITING
Trial end date:
2028-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2D\[s\]) of JNJ-87562761 in Part 1 (dose escalation), and to determine the safety and tolerability at RP2D in Part 2 (dose expansion) in participants with multiple myeloma (MM) whose disease has come back after treatment (relapsed) or hasn't responded to treatment (refractory).